Well Referenced

Tag: HSDD

Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women

The study titled “Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women” (Journal of Sexual Medicine, 2012, PMID: 22304681) reviews the effectiveness and safety of transdermal testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD). The findings suggest that transdermal testosterone

Read More »
June 26, 2025 No Comments

Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis

A systematic review and meta-analysis published in Fertility and Sterility (2017) evaluated the efficacy and safety of transdermal testosterone therapy in postmenopausal women with hypoactive sexual desire disorder (HSDD). The study found that transdermal testosterone significantly improved sexual function in both naturally and surgically menopausal women, regardless of concurrent estrogen-progestin

Read More »
June 26, 2025 No Comments

Flibanserin for hypoactive sexual desire disorder in premenopausal women

Flibanserin is a mixed 5-HT1A agonist and 5-HT2A antagonist approved for treating premenopausal women with hypoactive sexual desire disorder (HSDD). It is the first FDA-approved medication for this condition, showing efficacy by increasing the number of satisfying sexual events. However, flibanserin has been associated with side effects, including hypotension and

Read More »
June 26, 2025 No Comments